Agios Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Agios Pharmaceuticals (AGIO).

Price Target Range — 13 Quarters

Analyst Consensus — 10 Analysts

7Buy

3Hold

Consensus RatingBuy# Analysts10Avg. Consensus PT$45Upside to Avg. PT+42.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 7, 2026	Truist Securities	Gregory Renza	PT Cut	Buy	$39→$37
Sep 21, 2026	B of A Securities	Alec Stranahan	PT Raise	Buy	$46→$50
Aug 7, 2026	JP Morgan	Tessa Romero	PT Raise	Neutral	$31→$34
Jul 31, 2026	Citigroup	Samantha Semenkow	PT Raise	Buy	$46→$52
Jul 31, 2026	Truist Securities	Gregory Renza	PT Cut	Buy	$41→$39
Jul 30, 2026	HC Wainwright & Co.	Emily Bodnar	PT Raise	Buy	$52→$55
Jul 21, 2026	HC Wainwright & Co.	Emily Bodnar	PT Cut	Buy	$54→$52
Jul 7, 2026	RBC Capital	Luca Issi	PT Raise	Sector Perform	$28→$32
Jul 7, 2026	Truist Securities	Gregory Renza	PT Raise	Buy	$36→$41
Jul 7, 2026	B of A Securities	Alec Stranahan	PT Raise	Buy	$40→$46
Jun 15, 2026	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$54
Jun 11, 2026	JP Morgan	Tessa Romero	PT Cut	Neutral	$36→$31
May 29, 2026	B of A Securities	Greg Harrison	PT Cut	Buy	$41→$40
Apr 30, 2026	Truist Securities	Gregory Renza	PT Cut	Buy	$39→$36
Apr 21, 2026	B of A Securities	Greg Harrison	PT Cut	Buy	$44→$41
Apr 20, 2026	HC Wainwright & Co.	Emily Bodnar	PT Cut	Buy	$65→$50
Apr 6, 2026	JP Morgan	Tessa Romero	PT Raise	Neutral	$31→$36
Apr 1, 2026	Goldman Sachs	Salveen Richter	PT Raise	Neutral	$28→$32
Mar 5, 2026	Citigroup	Samantha Semenkow	PT Raise	Buy	$38→$46
Feb 12, 2026	HC Wainwright & Co.	Emily Bodnar	PT Raise	Buy	$62→$65

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Truist Securities Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $37

Truist Securities analyst Gregory Renza maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and lowers the price target from $39 to $37.

Benzinga Newsdesk

PRO
B of A Securities Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $50

B of A Securities analyst Alec Stranahan maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and raises the price target from $46 to $50.

Benzinga Newsdesk

PRO
JP Morgan Maintains Neutral on Agios Pharmaceuticals, Raises Price Target to $34

JP Morgan analyst Tessa Romero maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Neutral and raises the price target from $31 to $34.

Benzinga Newsdesk

PRO
Citigroup Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $52

Citigroup analyst Samantha Semenkow maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and raises the price target from $46 to $52.

Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $39

Truist Securities analyst Gregory Renza maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and lowers the price target from $41 to $39.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $55

HC Wainwright & Co. analyst Emily Bodnar maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and raises the price target from $52 to $55.

Benzinga Newsdesk

Agios Pharmaceuticals Inc

Agios Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Truist Securities Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $37

PRO
B of A Securities Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $50

PRO
JP Morgan Maintains Neutral on Agios Pharmaceuticals, Raises Price Target to $34

PRO
Citigroup Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $52

PRO
Truist Securities Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $39

PRO
HC Wainwright & Co. Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $55

People Also Watch

People Also Watch

Agios Pharmaceuticals Inc

Agios Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROTruist Securities Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $37

PROB of A Securities Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $50

PROJP Morgan Maintains Neutral on Agios Pharmaceuticals, Raises Price Target to $34

PROCitigroup Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $52

PROTruist Securities Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $39

PROHC Wainwright & Co. Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $55

People Also Watch

People Also Watch

PRO
Truist Securities Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $37

PRO
B of A Securities Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $50

PRO
JP Morgan Maintains Neutral on Agios Pharmaceuticals, Raises Price Target to $34

PRO
Citigroup Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $52

PRO
Truist Securities Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $39

PRO
HC Wainwright & Co. Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $55